Resources

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

A list of National Health and Medical Research Council (NHMRC) projects and the committed funding.

This fact sheet gives answers to common questions about the role of pharmacies and authorised persons in managing Life Saving Drugs Program (LSDP) medicines.

This presentation, delivered on 25 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

This data file contains statistical data about Australia's COVID-19 vaccinations.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

An update from the Council of Elders after their meeting on 8 and 9 December, 2022.

The meeting of the National Aged Care Advisory Council was held on 15 December 2022.

This spreadsheet classifies MBS items by private health insurance clinical category and procedure type and includes MBS items commencing 1 March 2023.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

This infographic issued on 20 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

This report, and accompanying table, provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 12 December 2022 to 8 January 2023

This presentation, delivered on 20 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

This data file contains statistical data about Australia's COVID-19 vaccinations.

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This chart shows the types of services provided as part of the Commonwealth Home Support Programme (CHSP).

This fact sheet provides advice on preparing a submission.